| 67 | Humans (MeSH) |
| 18 | Female (MeSH) |
| 17 | European Union (MeSH) |
| 17 | Europe (MeSH) |
| 15 | Adult (MeSH) |
| 14 | Disease Outbreaks (prevention & control) |
| 13 | Population Surveillance (methods) |
| 13 | Middle Aged (MeSH) |
| 13 | Male (MeSH) |
| 13 | Communicable Disease Control (organization & administration) |
| 12 | Disease Outbreaks (statistics & numerical data) |
| 12 | Bioterrorism (prevention & control) |
| 12 | Animals (MeSH) |
| 11 | Practice Guidelines as Topic (MeSH) |
| 11 | Bioterrorism (statistics & numerical data) |
| 8 | Luxembourg (epidemiology) |
| 7 | Child (MeSH) |
| 7 | Aged (MeSH) |
| 7 | Adolescent (MeSH) |
| 6 | Time Factors (MeSH) |
| 5 | Phylogeny (MeSH) |
| 5 | Molecular Sequence Data (MeSH) |
| 5 | Luxembourg (MeSH) |
| 5 | Blood Transfusion (standards) |
| 4 | Safety (MeSH) |
| 4 | Questionnaires (MeSH) |
| 4 | K562 Cells (MeSH) |
| 4 | International Cooperation (MeSH) |
| 4 | Infant, Newborn (MeSH) |
| 4 | Glutathione Transferase (genetics) |
| 4 | Genetic Variation (MeSH) |
| 4 | Child, Preschool (MeSH) |
| 3 | Transcription Factor AP-1 (metabolism) |
| 3 | Sensitivity and Specificity (MeSH) |
| 3 | Risk Management (organization & administration) |
| 3 | Quality Assurance, Health Care (organization & administration) |
| 3 | Public Health (MeSH) |
| 3 | Polymerase Chain Reaction (methods) |
| 3 | NF-kappa B (metabolism) |
| 3 | Isoenzymes (genetics) |
| 3 | Glutathione Transferase (metabolism) |
| 3 | Glutathione S-Transferase pi (MeSH) |
| 3 | Genotype (MeSH) |
| 3 | Gas Chromatography-Mass Spectrometry (MeSH) |
| 3 | European Union (organization & administration) |
| 3 | Enzyme-Linked Immunosorbent Assay (MeSH) |
| 3 | Blood Transfusion (adverse effects) |
| 3 | Binding Sites (MeSH) |
| 3 | Amino Acid Sequence (MeSH) |
| 3 | Age Distribution (MeSH) |
| 2 | World Health (MeSH) |
| 2 | U937 Cells (MeSH) |
| 2 | Tumor Necrosis Factor-alpha (pharmacology) |
| 2 | Tumor Cells, Cultured (MeSH) |
| 2 | Transfection (MeSH) |
| 2 | Tetradecanoylphorbol Acetate (pharmacology) |
| 2 | Signal Transduction (physiology) |
| 2 | Signal Transduction (drug effects) |
| 2 | Seroepidemiologic Studies (MeSH) |
| 2 | Risk Management (legislation & jurisprudence) |
| 2 | Risk Factors (MeSH) |
| 2 | Reproducibility of Results (MeSH) |
| 2 | Regression Analysis (MeSH) |
| 2 | RNA, Ribosomal, 16S (genetics) |
| 2 | RNA, Messenger (metabolism) |
| 2 | Prospective Studies (MeSH) |
| 2 | Program Evaluation (MeSH) |
| 2 | Prevalence (MeSH) |
| 2 | Pregnancy (MeSH) |
| 2 | Peptides (chemistry) |
| 2 | NF-kappa B (antagonists & inhibitors) |
| 2 | Mutation (MeSH) |
| 2 | Mice (MeSH) |
| 2 | Leukemia (MeSH) |
| 2 | Isoenzymes (metabolism) |
| 2 | Information Services (organization & administration) |
| 2 | Infant (MeSH) |
| 2 | Health Surveys (MeSH) |
| 2 | Hair (chemistry) |
| 2 | HIV-1 (genetics) |
| 2 | HIV Infections (drug therapy) |
| 2 | Gene Expression Regulation, Neoplastic (drug effects) |
| 2 | Gene Expression (drug effects) |
| 2 | GATA1 Transcription Factor (MeSH) |
| 2 | Fraxinus (genetics) |
| 2 | France (MeSH) |
| 2 | Forms and Records Control (MeSH) |
| 2 | Forecasting (MeSH) |
| 2 | Follow-Up Studies (MeSH) |
| 2 | Flow Cytometry (MeSH) |
| 2 | Exercise (MeSH) |
| 2 | Europe (epidemiology) |
| 2 | Erythroid-Specific DNA-Binding Factors (MeSH) |
| 2 | Environment (MeSH) |
| 2 | Data Collection (MeSH) |
| 2 | DNA, Viral (isolation & purification) |
| 2 | DNA Primers (MeSH) |
| 2 | Curcumin (pharmacology) |
| 2 | Cross-Sectional Studies (MeSH) |
| 2 | Congresses as Topic (MeSH) |
| 2 | Cluster Analysis (MeSH) |
| 2 | Chemoprevention (MeSH) |
| 2 | Carbohydrate Metabolism (MeSH) |
| 2 | Blood Transfusion (legislation & jurisprudence) |
| 2 | Blood Banks (organization & administration) |
| 2 | Biopsy (MeSH) |
| 2 | Antineoplastic Agents (pharmacology) |
| 2 | Anticonvulsants (therapeutic use) |
| 1 | Zinc (analysis) |
| 1 | Wounds and Injuries (therapy) |
| 1 | Wounds and Injuries (diagnosis) |
| 1 | World Health Organization (MeSH) |
| 1 | Water-Electrolyte Balance (MeSH) |
| 1 | Water Pollutants, Chemical (analysis) |
| 1 | Viral Structural Proteins (genetics) |
| 1 | Vinculin (chemistry) |
| 1 | Vertebral Artery Dissection (pathology) |
| 1 | Vertebral Artery Dissection (diagnosis) |
| 1 | Vehicle Emissions (adverse effects) |
| 1 | Vaginal Smears (statistics & numerical data) |
| 1 | Vaccines, Conjugate (immunology) |
| 1 | Vaccines (supply & distribution) |
| 1 | Vaccination (statistics & numerical data) |
| 1 | Vaccination (standards) |
| 1 | Uterine Cervical Neoplasms (pathology) |
| 1 | Uterine Cervical Neoplasms (epidemiology) |
| 1 | Urban Population (MeSH) |
| 1 | Unithiol (administration & dosage) |
| 1 | United States (MeSH) |
| 1 | Ultrasonography, Doppler, Transcranial (methods) |
| 1 | Ultrasonography, Doppler (MeSH) |
| 1 | Turkeys (virology) |
| 1 | Tularemia (therapy) |
| 1 | Tularemia (epidemiology) |
| 1 | Tularemia (diagnosis) |
| 1 | Transferrin (analysis) |
| 1 | Transferrin (analogs & derivatives) |
| 1 | Transcription, Genetic (MeSH) |
| 1 | Transcription Factors (physiology) |
| 1 | Transcription Factors (metabolism) |
| 1 | Transcription Factors (genetics) |
| 1 | Transcription Factors (chemistry) |
| 1 | Transcription Factors (antagonists & inhibitors) |
| 1 | Transcription Factor AP-1 (genetics) |
| 1 | Transcription Factor AP-1 (biosynthesis) |
| 1 | Transcription Factor AP-1 (antagonists & inhibitors) |
| 1 | Toxoplasmosis (immunology) |
| 1 | Toxoplasmosis (complications) |
| 1 | Toxoplasma (immunology) |
| 1 | Toxicology (trends) |
| 1 | Tomography, X-Ray Computed (MeSH) |
| 1 | Threshold Limit Values (MeSH) |
| 1 | Thalamus (radiography) |
| 1 | Thalamus (blood supply) |
| 1 | Telemedicine (trends) |
| 1 | Talin (chemistry) |
| 1 | T-Lymphocytes (immunology) |
| 1 | Symbiosis (MeSH) |
| 1 | Sweden (MeSH) |
| 1 | Surface Plasmon Resonance (MeSH) |
| 1 | Sulfur Hexafluoride (diagnostic use) |
| 1 | Sulfones (MeSH) |
| 1 | Substance-Related Disorders (epidemiology) |
| 1 | Substance-Related Disorders (classification) |
| 1 | Substance-Related Disorders (blood) |
| 1 | Substance Abuse Detection (methods) |
| 1 | Substance Abuse Detection (MeSH) |
| 1 | Stroke (therapy) |
| 1 | Stroke (epidemiology) |
| 1 | Stroke (diagnosis) |
| 1 | Street Drugs (blood) |
| 1 | Staphylococcal Infections (transmission) |
| 1 | Staphylococcal Infections (epidemiology) |
| 1 | Sports (MeSH) |
| 1 | Spectroscopy, Fourier Transform Infrared (methods) |
| 1 | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization (methods) |
| 1 | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization (MeSH) |
| 1 | Sodium Chloride (pharmacology) |
| 1 | Sociology, Medical (MeSH) |
| 1 | Socioeconomic Factors (MeSH) |
| 1 | Smoking (psychology) |
| 1 | Smoking (prevention & control) |
| 1 | Smoking (epidemiology) |
| 1 | Smallpox (therapy) |
| 1 | Smallpox (epidemiology) |
| 1 | Smallpox (diagnosis) |
| 1 | Skin (ultrastructure) |
| 1 | Skin (pathology) |
| 1 | Signal Transduction (MeSH) |
| 1 | Sex Distribution (MeSH) |
| 1 | Sequence Homology, Amino Acid (MeSH) |
| 1 | Sequence Analysis, DNA (MeSH) |
| 1 | Sequence Alignment (MeSH) |
| 1 | September 11 Terrorist Attacks (history) |
| 1 | Self Efficacy (MeSH) |
| 1 | Seafood (adverse effects) |
| 1 | School Health Services (standards) |
| 1 | School Health Services (organization & administration) |
| 1 | Scenedesmus (MeSH) |
| 1 | Salaries and Fringe Benefits (trends) |
| 1 | Salaries and Fringe Benefits (classification) |
| 1 | Safety Management (organization & administration) |
| 1 | Safety Management (legislation & jurisprudence) |
| 1 | Rural Population (MeSH) |
| 1 | Rubella (immunology) |
| 1 | Rubella (epidemiology) |
| 1 | Rubella (diagnosis) |
| 1 | Rubella (blood) |
| 1 | Rivers (chemistry) |
| 1 | Retrospective Studies (MeSH) |
| 1 | Respiratory Tract Infections (transmission) |
| 1 | Respiratory Tract Infections (microbiology) |
| 1 | Residence Characteristics (statistics & numerical data) |
| 1 | Reptiles (microbiology) |
| 1 | Recombinant Fusion Proteins (metabolism) |
| 1 | Recombinant Fusion Proteins (immunology) |
| 1 | Randomized Controlled Trials as Topic (MeSH) |
| 1 | Radioactive Pollutants (standards) |
| 1 | Radiation Protection (standards) |
| 1 | Radiation Protection (methods) |
| 1 | Rabies virus (pathogenicity) |
| 1 | Rabies virus (immunology) |
| 1 | Rabies virus (genetics) |
| 1 | Rabies (veterinary) |
| 1 | Rabies (prevention & control) |
| 1 | Rabies (epidemiology) |
| 1 | RNA, Viral (blood) |
| 1 | RNA, Ribosomal, 16S (analysis) |
| 1 | RNA, Messenger (genetics) |
| 1 | RNA, Bacterial (genetics) |
| 1 | RNA Stability (MeSH) |
| 1 | Quality Assurance, Health Care (legislation & jurisprudence) |
| 1 | Quality Assurance, Health Care (MeSH) |
| 1 | Q Fever (therapy) |
| 1 | Q Fever (epidemiology) |
| 1 | Q Fever (diagnosis) |
| 1 | Public Sector (economics) |
| 1 | Psychotropic Drugs (blood) |
| 1 | Psychotic Disorders (etiology) |
| 1 | Proteomics (MeSH) |
| 1 | Proteins (chemistry) |
| 1 | Proteins (analysis) |
| 1 | Protein Structure, Tertiary (MeSH) |
| 1 | Protein Precursors (genetics) |
| 1 | Protein Kinase Inhibitors (MeSH) |
| 1 | Protein Binding (MeSH) |
| 1 | Promoter Regions, Genetic (drug effects) |
| 1 | Promoter Regions, Genetic (MeSH) |
| 1 | Proline (metabolism) |
| 1 | Private Sector (economics) |
| 1 | Pregnancy Complications (physiopathology) |
| 1 | Predictive Value of Tests (MeSH) |
| 1 | Precancerous Conditions (pathology) |
| 1 | Precancerous Conditions (epidemiology) |
| 1 | Poultry Diseases (virology) |
| 1 | Poultry Diseases (prevention & control) |
| 1 | Poultry Diseases (epidemiology) |
| 1 | Portugal (MeSH) |
| 1 | Populus (physiology) |
| 1 | Populus (metabolism) |
| 1 | Populus (growth & development) |
| 1 | Populus (drug effects) |
| 1 | Population Surveillance (MeSH) |
| 1 | Polymorphism, Restriction Fragment Length (MeSH) |
| 1 | Polyamines (metabolism) |
| 1 | Pollen (genetics) |
| 1 | Poisons (MeSH) |
| 1 | Platelet Glycoprotein GPIIb-IIIa Complex (metabolism) |
| 1 | Platelet Aggregation (physiology) |
| 1 | Platelet Aggregation (drug effects) |
| 1 | Platelet Activation (physiology) |
| 1 | Plant Proteins (physiology) |
| 1 | Plant Proteins (isolation & purification) |
| 1 | Plant Leaves (physiology) |
| 1 | Plague (therapy) |
| 1 | Plague (epidemiology) |
| 1 | Plague (diagnosis) |
| 1 | Physicians (supply & distribution) |
| 1 | Phospholipids (diagnostic use) |
| 1 | Philosophy (MeSH) |
| 1 | Philately (MeSH) |
| 1 | Perception (MeSH) |
| 1 | Peptides (immunology) |
| 1 | Peptides (analysis) |
| 1 | Patient Compliance (MeSH) |
| 1 | Patient Care Team (MeSH) |
| 1 | Parvalbumins (immunology) |
| 1 | Particle Size (MeSH) |
| 1 | Oxides (therapeutic use) |
| 1 | Oxides (pharmacology) |
| 1 | Oxides (adverse effects) |
| 1 | Oxidation-Reduction (MeSH) |
| 1 | Organizational Policy (MeSH) |
| 1 | Organizational Objectives (MeSH) |
| 1 | Organic Chemicals (pharmacology) |
| 1 | Occupational Exposure (MeSH) |
| 1 | Occupational Diseases (etiology) |
| 1 | Occult Blood (MeSH) |
| 1 | Nitrogen (analysis) |
| 1 | Nitriles (MeSH) |
| 1 | Nigeria (epidemiology) |
| 1 | Netherlands (MeSH) |
| 1 | Neoplasms (prevention & control) |
| 1 | Neoplasms (metabolism) |
| 1 | Neoplasms (drug therapy) |
| 1 | Neoplasm Staging (MeSH) |
| 1 | Needs Assessment (MeSH) |
| 1 | National Health Programs (organization & administration) |
| 1 | NF-kappa B (physiology) |
| 1 | Mutagenesis, Site-Directed (MeSH) |
| 1 | Music (history) |
| 1 | Mumps virus (immunology) |
| 1 | Mumps (immunology) |
| 1 | Mumps (epidemiology) |
| 1 | Mumps (diagnosis) |
| 1 | Mumps (blood) |
| 1 | Multivariate Analysis (MeSH) |
| 1 | Motor Activity (MeSH) |
| 1 | Models, Genetic (MeSH) |
| 1 | Models, Econometric (MeSH) |
| 1 | Models, Biological (MeSH) |
| 1 | Mineral Fibers (toxicity) |
| 1 | Milk Proteins (metabolism) |
| 1 | Milk (cytology) |
| 1 | Milk (chemistry) |
| 1 | Microscopy, Fluorescence (methods) |
| 1 | Microsatellite Repeats (genetics) |
| 1 | Microsatellite Repeats (MeSH) |
| 1 | Microbial Sensitivity Tests (methods) |
| 1 | Mice, Inbred CBA (MeSH) |
| 1 | Methicillin Resistance (MeSH) |
| 1 | Metals (analysis) |
| 1 | Mesencephalon (radiography) |
| 1 | Mesencephalon (blood supply) |
| 1 | Mercury (urine) |
| 1 | Mental Health Services (legislation & jurisprudence) |
| 1 | Melioidosis (therapy) |
| 1 | Melioidosis (epidemiology) |
| 1 | Melioidosis (diagnosis) |
| 1 | Medical Records (standards) |
| 1 | Medical Errors (MeSH) |
| 1 | Measles-Mumps-Rubella Vaccine (standards) |
| 1 | Measles virus (immunology) |
| 1 | Measles virus (genetics) |
| 1 | Measles virus (classification) |
| 1 | Measles Vaccine (immunology) |
| 1 | Measles (immunology) |
| 1 | Measles (epidemiology) |
| 1 | Measles (diagnosis) |
| 1 | Measles (blood) |
| 1 | Maximum Allowable Concentration (MeSH) |
| 1 | Mastication (MeSH) |
| 1 | Mastectomy (MeSH) |
| 1 | Mass Screening (organization & administration) |
| 1 | Mass Screening (MeSH) |
| 1 | Malondialdehyde (metabolism) |
| 1 | Male Urogenital Diseases (MeSH) |
| 1 | Luminescent Proteins (pharmacology) |
| 1 | Luminescent Proteins (metabolism) |
| 1 | Longitudinal Studies (MeSH) |
| 1 | Logistic Models (MeSH) |
| 1 | Linkage Disequilibrium (MeSH) |
| 1 | Language (MeSH) |
| 1 | Lactation (physiology) |
| 1 | Lactation (genetics) |
| 1 | Kinetics (MeSH) |
| 1 | Jurkat Cells (MeSH) |
| 1 | Isoenzymes (biosynthesis) |
| 1 | Ireland (MeSH) |
| 1 | Interviews as Topic (MeSH) |
| 1 | Internet (MeSH) |
| 1 | International Agencies (organization & administration) |
| 1 | Integrin beta Chains (chemistry) |
| 1 | Injections, Intravenous (MeSH) |
| 1 | Infectious bursal disease virus (pathogenicity) |
| 1 | Infectious bursal disease virus (genetics) |
| 1 | Infectious bursal disease virus (chemistry) |
| 1 | Infectious Disease Transmission, Vertical (MeSH) |
| 1 | Infection Control (standards) |
| 1 | Infection Control (organization & administration) |
| 1 | Infection Control (methods) |
| 1 | Infection Control (legislation & jurisprudence) |
| 1 | Infant Mortality (trends) |
| 1 | Income (classification) |
| 1 | Income (MeSH) |
| 1 | Immunoglobulin M (blood) |
| 1 | Immunoglobulin G (blood) |
| 1 | Immunoglobulin E (immunology) |
| 1 | Immunoglobulin E (blood) |
| 1 | Immunization, Secondary (MeSH) |
| 1 | Immunization, Passive (MeSH) |
| 1 | Immunization Schedule (MeSH) |
| 1 | Image Processing, Computer-Assisted (MeSH) |
| 1 | Ice Cover (MeSH) |
| 1 | Hypersensitivity, Immediate (prevention & control) |
| 1 | Hypersensitivity, Immediate (etiology) |
| 1 | Hyperplasia (pathology) |
| 1 | Hyperplasia (epidemiology) |
| 1 | Hydroquinones (pharmacology) |
| 1 | Hydrogen Peroxide (pharmacology) |
| 1 | Home Care Services (MeSH) |
| 1 | History, 21st Century (MeSH) |
| 1 | History, 19th Century (MeSH) |
| 1 | History, 18th Century (MeSH) |
| 1 | Herpesvirus 3, Human (pathogenicity) |
| 1 | Hepatitis B virus (isolation & purification) |
| 1 | Hepatitis B virus (genetics) |
| 1 | Hepatitis B Surface Antigens (genetics) |
| 1 | Hepatitis B (virology) |
| 1 | Hepatitis B (transmission) |
| 1 | Hepatitis B (epidemiology) |
| 1 | Hemorrhagic Fevers, Viral (therapy) |
| 1 | Hemorrhagic Fevers, Viral (epidemiology) |
| 1 | Hemorrhagic Fevers, Viral (diagnosis) |
| 1 | Hemin (pharmacology) |
| 1 | Health Planning Guidelines (MeSH) |
| 1 | Health Physics (trends) |
| 1 | Health Physics (standards) |
| 1 | Health Education (standards) |
| 1 | Health Education (organization & administration) |
| 1 | Health Care Sector (MeSH) |
| 1 | Haplotypes (MeSH) |
| 1 | Hand Injuries (surgery) |
| 1 | Hand Injuries (epidemiology) |
| 1 | Hand Injuries (economics) |
| 1 | Half-Life (MeSH) |
| 1 | HIV-1 (drug effects) |
| 1 | HIV Reverse Transcriptase (genetics) |
| 1 | HIV Protease (genetics) |
| 1 | HIV Infections (virology) |
| 1 | Green Fluorescent Proteins (MeSH) |
| 1 | Great Britain (MeSH) |
| 1 | Government Agencies (organization & administration) |
| 1 | Glutathione Transferase (biosynthesis) |
| 1 | Glucuronates (analysis) |
| 1 | Glanders (therapy) |
| 1 | Glanders (epidemiology) |
| 1 | Glanders (diagnosis) |
| 1 | Germany (epidemiology) |
| 1 | Germany (MeSH) |
| 1 | Geologic Sediments (analysis) |
| 1 | Geography (MeSH) |
| 1 | Genetics, Population (MeSH) |
| 1 | Genetic Markers (MeSH) |
| 1 | Genes, Viral (MeSH) |
| 1 | Gene Frequency (MeSH) |
| 1 | Gene Expression Regulation, Enzymologic (drug effects) |
| 1 | Functional Laterality (physiology) |
| 1 | Fraxinus (classification) |
| 1 | France (epidemiology) |
| 1 | Foxes (virology) |
| 1 | Fossils (MeSH) |
| 1 | Forensic Medicine (methods) |
| 1 | Forensic Medicine (MeSH) |
| 1 | Food Hypersensitivity (immunology) |
| 1 | Food Hypersensitivity (blood) |
| 1 | Food Contamination (MeSH) |
| 1 | Fluorescent Antibody Technique, Indirect (MeSH) |
| 1 | Fluorescence Resonance Energy Transfer (methods) |
| 1 | Fishes (microbiology) |
| 1 | Fishes (immunology) |
| 1 | Finland (MeSH) |
| 1 | Filtration (MeSH) |
| 1 | Fibrillar Collagens (ultrastructure) |
| 1 | Female Urogenital Diseases (microbiology) |
| 1 | Female Urogenital Diseases (complications) |
| 1 | Fatty Acids (analysis) |
| 1 | Fats (metabolism) |
| 1 | Family Planning Services (methods) |
| 1 | Eye Infections (microbiology) |
| 1 | Ethanol (blood) |
| 1 | Escherichia coli (metabolism) |
| 1 | Erythrocytes (drug effects) |
| 1 | Epilepsy (drug therapy) |
| 1 | Epilepsy (complications) |
| 1 | Epidemiology (MeSH) |
| 1 | Enzyme Activation (MeSH) |
| 1 | Environmental Pollution (prevention & control) |
| 1 | Environmental Monitoring (methods) |
| 1 | Environmental Monitoring (MeSH) |
| 1 | Environmental Microbiology (MeSH) |
| 1 | Environmental Exposure (adverse effects) |
| 1 | Environmental Exposure (MeSH) |
| 1 | Endemic Diseases (MeSH) |
| 1 | Encephalitis, Viral (therapy) |
| 1 | Encephalitis, Viral (epidemiology) |
| 1 | Encephalitis, Viral (diagnosis) |
| 1 | Emergency Service, Hospital (MeSH) |
| 1 | Emergency Medical Services (organization & administration) |
| 1 | Emergencies (MeSH) |
| 1 | Electrophoretic Mobility Shift Assay (MeSH) |
| 1 | Electrophoresis, Gel, Two-Dimensional (MeSH) |
| 1 | Elastic Tissue (ultrastructure) |
| 1 | Elastic Tissue (pathology) |
| 1 | Ehlers-Danlos Syndrome (pathology) |
| 1 | Drug Resistance, Viral (genetics) |
| 1 | Drug Resistance, Microbial (MeSH) |
| 1 | Drug Interactions (MeSH) |
| 1 | Drug Delivery Systems (methods) |
| 1 | Doxorubicin (pharmacology) |
